ERLEADA is indicated: in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see Pharmacology: Pharmacodynamics under Actions); in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in
combination with androgen deprivation therapy (ADT) (see Pharmacology: Pharmacodynamics under Actions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
